Structural and molecular interactions of CCR5 inhibitors with CCR5.
about
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loopBinding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonistsElucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5.P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor InteractionsSolution Structure of LC4 Transmembrane Segment of CCR5Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction networkLigand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptorThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsHIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsStructural Analysis of Chemokine Receptor-Ligand Interactions.New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infectionA pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitorsClinical use of CCR5 inhibitors in HIV and beyondHIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropismInsights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drugCCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.Analysis of Chemokine Receptor Trafficking by Site-Specific BiotinylationCCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsA common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTInvolvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5.Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Pharmacological modulation of chemokine receptor function.Specific microbicides in the prevention of HIV infection.
P2860
Q21559473-4EE3DB98-E1E1-48E9-BC62-1DE040046D83Q24658283-51AF677C-E419-4C09-93FE-11AC062DDC7CQ27309182-D833D1F0-137F-45EB-B779-B2453728A646Q27321418-52CF9282-12E4-45F7-B61D-D6D56650D721Q27666261-63681968-FA0B-429D-B112-8BA266B255C6Q28533728-6B511B26-E795-4ACF-9836-8EB7E98794CAQ30366048-95A91C46-4E1A-4281-9BE6-7D603BEB5A76Q30486707-0C21224F-19B1-4D15-B9B1-E6F40A5D4E9EQ33807529-B3481C21-1858-4F09-A927-E6C2FA16FB02Q33890786-9633596E-FEFC-4879-A956-7346DA1C1A59Q33961704-A897C776-C2CA-49C4-8C66-A5A11FF41868Q33990552-61D70372-F05B-424E-8D3D-129BDB20E21AQ34550666-1B1BCD14-E88F-44AE-BD91-413950091F56Q34568280-801809D2-37C4-435D-93D4-0D2A08589099Q34606129-A652BE74-109A-4A3A-9ECC-7076894944FAQ34610959-EAF06856-5C76-469D-BA86-9BBE96D17B0FQ34641781-74D7A784-B903-4D47-BB27-A0C94AD92B9BQ35018145-37F6C78C-9B9D-472C-A42E-3659C80CC9FCQ35076868-AA497D40-EE98-4D00-995B-2960196F4013Q35168976-C7DA3A67-C060-4853-B0FC-DFFDB56525B6Q35312348-BD8F8BAE-4672-450B-AA58-962CACD28523Q35665842-8DD5A72D-0665-4378-876B-8393AEEF6822Q35911313-D9DD1FBB-CFE7-4502-907F-4F72C3969F4CQ35922555-2A5B4EF9-EF7F-4866-A03E-EA0A2DED8C8FQ36054360-54E9F190-FBA6-43C7-99D1-8BD790CB4651Q36246273-0B5861D0-5FF3-4630-A8B1-8F3F7B3E98A3Q36419287-73C0E046-ED77-4EEA-B72D-A498D9D793A4Q36703042-0825F5AC-6A3D-47F2-84FF-68BF39333902Q36827946-F682C3B8-8345-484B-BA51-E0A5971CC6DEQ36900010-0954B8FB-47E0-4EA1-8000-8EEDF0781B7DQ37071732-2FC7950F-4297-47F2-AAC5-6DD82977FC7CQ37360436-C96269E2-9E35-4CE6-B15E-07DD7F3396FBQ37421895-A90BF7D4-8C81-48BF-9312-2CF73D56E635Q37452124-D0C7EA13-4DA3-4180-9E9B-C97D40C24B39Q37463869-4154C786-776D-4CF0-B109-3D5469A34FD8Q37502946-D8C874BB-FF05-4BAF-B80A-D599751E759DQ37780220-531632E6-DF05-46D4-985E-1C83E71906E9Q37855900-181F4576-2672-47BF-B1FD-5437BEDCC220Q37893687-1A0C69A5-6FA7-465D-AF58-47D4DEE46B23Q37932048-7407849D-4BB8-413D-BCCF-9090430F4E09
P2860
Structural and molecular interactions of CCR5 inhibitors with CCR5.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@ast
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@en
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@nl
type
label
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@ast
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@en
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@nl
prefLabel
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@ast
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@en
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@nl
P2093
P2860
P356
P1476
Structural and molecular interactions of CCR5 inhibitors with CCR5.
@en
P2093
Debananda Das
Eddy Arnold
Gail F Arnold
Hiroaki Mitsuya
Hiromi Ogata-Aoki
Hirotomo Nakata
Jianping Ding
Kenji Maeda
Rachael Norman
Toshikazu Miyakawa
P2860
P304
12688-12698
P356
10.1074/JBC.M512688200
P407
P577
2006-02-13T00:00:00Z